Industry / innovation partners

Divarasib Raises the KRAS G12C Bar

AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Precision Oncology Has a Scale Problem

Food Safety Gets A Political Upgrade

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

The Pandemic Deal Has A Hole.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
